Skip to content

Clinical study on the application of esketamine to parturients in caesarean section under general anesthesia

Clinical study on the application of esketamine to parturients in caesarean section under general anesthesia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078490
Enrollment
Unknown
Registered
2023-12-11
Start date
2023-12-15
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum depression

Interventions

Control group:During induction, 5ml normal saline, 2mg·kg-1 propofol, 4ng·ml-1 remifentanil and 0.6mg·kg-1 rocurium bromide were administered intravenously
Esketamine group:The patients were induced to receive esketamine 0.25mg·kg-1 diluted to 5ml, propofol 2mg·kg-1, remifentanil 4ng·ml-1 effect chamber target concentration controlled infusion (TCI), roc

Sponsors

The Fourth Hospital of Shijiazhuang
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) ASA grade II-III; (2) Before starting activities related to the test, voluntarily sign informed consent, fully understand the purpose and significance of the test, and voluntarily comply with the test procedure; (3) Subjects who intend to undergo elective cesarean section under general anesthesia; (4) 18 years old =40 years old; (5) Expected duration of surgery =2h; (6) Prenatal body mass index (BMI) <35kg/m2 after pregnancy.cy.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of stroke, cognitive dysfunction and epilepsy; (2) Patients with a history of myocardial infarction, angina pectoris, or a history of degree II or above atrioventricular block and other severe arrhythmias within 6 months before screening; (3) pregnancy combined with other diseases (malignant tumor, pregnancy-induced hypertension, thyroid dysfunction, etc.); (4) Peripheral blood oxygen saturation (SpO2) was less than 92% in the non-oxygenated state; (5) Continuous use of sedative, analgesic and hypnotic drugs for 3 months before randomization.

Design outcomes

Primary

MeasureTime frame
EPDS score;

Secondary

MeasureTime frame
VAS score;MAP;

Countries

China

Contacts

Public ContactZhang Jin

The Fourth Hospital of Shijiazhuang

morningzhangj@163.com+86 151 3313 0681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026